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The role of IL-6 in collagen production and tissue re-
modeling is controversial. In Rat-1 fibroblasts, we meas-
ured the effect of IL-6 on matrix metalloproteinase-13
(MMP-13), c-jun, junB, and c-fos gene expression, bind-
ing of activator protein 1 (AP1) to DNA, amount of AP1
proteins, immunoreactive MMP-13 and TIMP-1 proteins,
and Jun N-terminal kinase activity. We show that IL-6
increased MMP-13-mRNA and MMP-13 protein. These
effects were exerted by acting on the AP1-binding site of
the MMP-13 promoter, as shown by transfecting cells
with reporter plasmids containing mutations in this el-
ement. Mobility shift assays demonstrated that IL-6 in-
duced the DNA binding activity of AP1. This effect was
accompanied by a marked increase in c-Jun, JunB, and
c-Fos mRNA, as well as in c-Jun protein and its phospho-
rylated form. The latter is not due to increased Jun
N-terminal kinase activity but to a decreased serine/
threonine phosphatase activity. We conclude that IL-6
increases interstitial MMP-13 gene expression at the
promoter level. This effect seems to be mediated by the
induction of c-jun, junB, and c-fos gene expression, by
the binding of AP1 to DNA, by increasing phosphoryl-
ated c-Jun, and by the inhibition of serine/threonine
phosphatase activity. These effects of IL-6 might con-
tribute to remodeling connective tissue.
Interleukin-6 (IL-6)1 is a multifunctional glycoprotein pro-
duced by activated monocytes, macrophages, endothelial cells,
and hepatic stellate cells that induces a wide variety of biolog-
ical activities on many kinds of target cells, including fibro-
blasts, hepatocytes, and hepatic stellate cells (1). IL-6 promotes
cell growth and differentiation and regulates specific gene ex-
pression of a variety of cells (2). IL-6 induces the expression of
the acute phase proteins in the liver by inducing the binding of
NF-IL6 and STAT3 to the promoter region of acute phase genes
and promotes a rapid and transient tyrosine phosphorylation of
the cytoplasmic domains of the IL-6 receptor (gp130) (1, 3).
Acute and chronic liver diseases, particularly alcoholic liver
diseases, are similar to the acute phase response in some re-
spects. Thus, patients with acute alcoholic hepatitis show fever,
muscle wasting, neutrophilia, and increased production of C-
reactive protein, a1-antitrypsin, and amyloid A (4, 5). High
levels of IL-6 have been detected in the sera of patients with
alcoholic liver cirrhosis (6–8), hepatitis B virus infection (9),
and acute hepatitis (10, 11). Some authors have shown a cor-
relation between circulating concentrations of IL-6 and serum
concentrations of C-reactive protein (12, 13). Thus, IL-6 seems
to be one of the most important factors regulating inflamma-
tory responses in the liver.
Matrix metalloproteinases (MMPs) constitute a family of
structurally related zymogens (collagenase-1 (MMP-1), colla-
genase-3 (MMP-13), gelatinases A and B (MMP-2 and MMP-9),
and stromelysin (MMP-3), among others) capable of degrading
a wide variety of extracellular matrix components (14). In rats
and mice, there is only one interstitial collagenase (MMP-13); it
shares 86% homology with human MMP-13 but not with the
human or rabbit MMP-1 (15, 16). A variety of biologically active
agents, such as tumor necrosis factor-a and interleukin-1, mod-
ulates the synthesis of these enzymes and their natural inhib-
itors, tissue inhibitors of MMP (TIMPs) (17–19). Although IL-6
shares many biological activities with IL-1, the role of IL-6 on
the regulation of synthesis of MMPs and TIMPs remains con-
troversial (17, 20–22). Whereas some authors found evidence
for increased collagenase production (20, 23–25), others could
not demonstrate any effect of IL-6 on the expression of MMP
(21) or showed that IL-6 induces the synthesis of TIMP (17, 22,
26–28). We have undertaken the present study to elucidate the
effect of IL-6 on rat MMP-13 (collagenase-3) gene expression in
Rat-1 fibroblasts. We demonstrate that this cytokine stimu-
lates MMP-13 expression by acting on an AP1-binding site in
the MMP-13 promoter, after inducing the synthesis and phos-
phorylation of AP1 proteins.
EXPERIMENTAL PROCEDURES
Cell Culture—Rat-1 fibroblasts obtained from American Type Cul-
ture Collection were grown at 37 °C in an atmosphere of 5% CO2, 95%
air in cell culture flasks using 10 ml of Dulbecco’s minimum essential
medium with Earle’s salts (Life Technologies, Inc.) containing 5% fetal
bovine serum (Flow, Irvine, Ayrshire, Scotland), 0.5 mg/ml L-glutamine,
100 units/ml penicillin G and 0.1 mg/ml streptomycin. In some experi-
ments we used protein extract from J-Jahn cells (29). This is a human
lymphoblastoid cell line derived from Jurkat cells that expresses large
amount of c-Jun after being stimulated with phorbol 12-myristrate
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13-acetate (PMA). This cell line was a gift from Dr. J. Alcami (Madrid,
Spain) (29).
Recombinant Plasmids—The luciferase reporter gene p2TRE-Luc
contains two copies of the 12-O-tetradecanoylphorbol-13-acetate-re-
sponsive element (TRE) upstream of the herpes simplex virus-tk pro-
moter (30) (gift of K. Chien, University of California, San Diego, CA)
inserted into p19-Luc. pMMP-13-CAT plasmids (p(22200) MMP-13-
CAT, p(21000)MMP-13-CAT, p(2500)MMP-13-CAT, p(2284)MMP-13-
CAT, and p(276)MMP-13-CAT) contain 76 base pairs to 2.2 kilobase
pairs 59-flanking DNA of the MMP-13 gene promoter inserted into a
vector that encodes the enzyme chloramphenicol acetyltransferase
(CAT) (pSVO-CAT) (31). p(276)MMP-13-CATm is a construct similar to
p(276)MMP-13-CAT, but containing a TRE, in which the wild-type
sequence GTGACTCA have been scrambled into GTTCCAAG. pFos-Luc
contains the HindIII/XbaI fragment (760 base pairs) of the human c-fos
promoter inserted into p19-Luc (32). Construction of pRSV-b-galacto-
sidase containing the Rous sarcoma virus (RSV) promoter and the
b-galactosidase reporter gene has been described elsewhere (32). pJun-
Luc contains the SaltI fragment (2.2 kilobase pairs) of the human c-Jun
promoter inserted into p19-Luc vector (33). Human pBR 18 S contains
the EcoRI fragment (5.8 kilobase pairs) subcloned into the pBR 322
vector.
Transfection and Luciferase Assays—Rat 1 fibroblasts were tran-
siently transfected by the LipofectAMINE technique. Briefly, after
overnight incubation, cells were washed twice with Opti-MEM medium
(Life Technologies, Inc.) and incubated with a cotransfection mix con-
taining 1.5 mg of CAT plasmids and 11 mg of LipofectAMINE reagent
(Life Technologies, Inc.) in Opti-MEM medium at 37 °C for 8 h. After
incubation, the transfection mix was aspirated and replaced with
growth medium containing 10% fetal calf serum. After 24 h, the cells
were washed with phosphate-buffered saline, and a new medium with-
out fetal calf serum was added. After 2 h, cells were treated with IL-6
for various periods of time. Afterward, cells were washed with cold
phosphate-buffered saline. Cell lysates were prepared, and CAT activ-
ity was determined as described elsewhere (34). Because CAT activity
in cells transfected with constructs containing the smaller portions of
the MMP-13 promoter was very low, the amount of cell lysate used for
the CAT assays was 2 (p(2500)MMP-13-CAT), 8 (p(2284)MMP-13-
CAT), and 18 times higher (p(276)MMP-13-CAT and p(276)MMP-13-
CATm) than the amount of cell lysate used when cells were transfected
with p(21000)MMP-13-CAT or p(22000)MMP-13-CAT constructs. In
some experiments, cells were cotransfected with 0.5 mg of luciferase
reporter plasmids and 0.5 mg of b-galactosidase pRSV-b-galactosidase
as an internal control of transfection efficiency. In these cases, lucifer-
ase activity was determined using the enhanced luciferase assay kit
according to the manufacturer’s protocol (Analytical Luminescence, San
Diego, CA). Cell lysates were prepared in 125 ml of of cell lysis buffer.
Luciferase activity was determined using 50-ml aliquots, and protein
concentrations determined with 5-ml aliquots using the Bradford pro-
tein assay (Bio-Rad). Published procedures were used to measure b-ga-
lactosidase activity (35). Transfections were performed in duplicate or
triplicate.
RNA Preparation and Northern Analysis—Total RNA was prepared
from cultured Rat-1 fibroblasts as described by Chomczynski and
Sacchi (36). Five-microgram RNA samples were separated by electro-
phoresis on 2.2 M formaldehyde, 1% agarose gels and transferred to
nylon membranes (MSI, Westboro, MA). cDNA probes for rat inter-
stitial collagenase, c-Jun (37), JunB (38), and c-Fos (39) and 18 S RNA
(EcoRI fragment of the pBR322 plasmid) were labeled using a random
priming DNA labeling kit (Roche Molecular Biochemicals). Membranes
were hybridized and washed with a final stringency of 0.13 SSC, 0.1%
SDS and then analyzed by autoradiography. The autoradiograms were
quantitated by scanning laser densitometry (Desk TopTM Scanner Plus,
Amersham Pharmacia Biotech).
Preparation of Nuclear Extracts and Gel Mobility Shift Assays—
Nuclear proteins from Rat-1 fibroblasts untreated and treated with IL-6
were extracted by the method of Dignam et al. (40). The pellet was
resuspended in 50 ml of Dignam C buffer and protein concentration was
determined by the Bio-Rad assay according to the manufacturer’s in-
structions. An oligonucleotide representing the consensus AP1 binding
site from the human collagenase gene (41) was synthesized with a
Cyclone Plus oligonucleotide synthesizer (Milligen, Novato, CA) and
purified by high-performance liquid chromatography. The DNA se-
quences of this oligonucleotide were as follows: sense, 59-TAAAGCAT-
GAGTCAGACACCTC-39; antisense, 39-ATTTCGTACTCAGTCTGTG-
GAG-59. Double-stranded oligonucleotides probes were end labeled
using the Klenow fragment and [32P]dCTP (Amersham Pharmacia Bio-
tech). Prior to adding 32P-labeled oligonucleotides, 10 mg of nuclear
protein extracts were incubated for 15 min with a mixture of 8 ml of a
mixture mixture containing 0.5 ml of 5 mg/ml poly(dI-dC) (Roche Mo-
lecular Biochemicals), 1 ml of 100 mM MgCl2, and 6.5 ml of distilled H2O
in the presence of 23 NDB (20 mM Hepes, pH 7.6, 100 mM KCl, 0.2 mM
EDTA, 2 mM dithiothreitol, 20% glycerol). End-labeled oligonucleotides
(20,000 cpm) were incubated with this mixture for 20 min. For compe-
tition experiments, 200-fold unlabeled annealed oligonucleotide was
added to binding reactions. The autoradiograms were quantitated by
scanning laser densitometry.
Western Blot Analysis—Whole cell protein extracts were prepared
from Rat 1 fibroblasts and PMA-treated Junkat cells cultured on plastic
until confluency. Cells were washed with phosphate-buffered saline and
lysed by adding an equal volume of Dignam C buffer (40). After mixing
at 4 °C for 30 min, the samples were centrifuged at 16,000 3 g for 5 min
at 4 °C, and the supernatant was collected and stored at 280 °C. For
the analysis of cell free MMP-13 protein level, culture medium from
cells unstimulated or stimulated with 20 and 40 ng/ml IL-6 for 24 h in
Dulbecco’s modified Eagle’s medium without fetal calf serum was col-
lected and centrifuged at 1500 3 g to remove particles. For the analysis
of TIMP-1 protein level, 500 ml of culture medium, after being centri-
fuged, were concentrated to 20 ml (Microcon-10 concentrator, Amicon,
Beverly, MA). Protein assays were performed using the Bradford assay
(Bio-Rad). Proteins (25 mg) were separated in an 8% SDS-polyacryl-
amide gel and transferred onto an Immobilon membrane (Millipore,
Bedford, MA) overnight at 30 V at 4 °C. Equal loading was confirmed by
Ponceau S staining. After electrotransfer the filter was incubated in
Blotto (5% nonfat dry milk in TBS-Tween 20 (25 mmol/liter Tris-HCl,
pH 8.0, 144 mmol/liter NaCl, 0.075% Tween-20)) overnight at 4 °C. The
filter was then washed three times, 7 min each wash, in TBS-Tween 20
at 4 °C. The filter was then incubated with polyclonal MMP-13, (Chemi-
con International Inc. Temecula. CA), TIMP-1, C/EBP, c-Jun, or c-Fos
antibodies or monoclonal phosphorylated c-Jun antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA.) at 1:400 (diluted in Blotto) for 2 h at
4 °C. The polyclonal MMP-13 antibody reacts with human and rat
MMP-13 protein, whereas TIMP-1 antibody was specific for rat protein.
c-Jun, phosphorylated c-Jun, C/EBP, and c-Fos antibodies react with
rat as well as with human and mouse proteins. The filter was washed
with TBS-Tween 20, as described previously, and then incubated with
the secondary antibody, goat anti-rabbit-IgG-alkaline phosphatase
(Amersham Pharmacia Biotech) diluted 1:2000 in Blotto for 1 h at 4 °C.
The filter was washed, incubated at room temperature with Western
Blue Stabilized Substrate for Alkaline Phosphatase (Promega, Madi-
son. WI) for approximately 1 min, and finally rinsed with water.
Kinase Assay—c-Jun N-terminal kinase (JNK) assay were performed
as described (41). Briefly, 20 mg of whole cell protein were incubated
with recombinant GST-c-Jun substrate (amino acids 1–79) (42) conju-
gated to glutathione-agarose beads (Amersham Pharmacia Biotech),
extensively washed, and then incubated in kinase reactions containing
[g-32P]ATP as a phosphate donor. Substrate protein was resolved by gel
electrophoresis, and phosphate incorporation was assessed by autora-
diography and phosphorimager analysis.
Serine/Threonine Phosphatase Assay—Untreated or IL-6-treated
Rat-1 fibroblasts were washed three times with ice-cold phosphate-
buffered saline and lysed in Dignam C buffer lacking phosphatase
inhibitors (sodium molibdate, sodium vanadate, b-glycerophosphate,
and p-nitrophenylphosphate). Endogenous phosphates were removed
by passing cell lysate through a Sephadex G-25 spin column. Protein
concentration of the phosphate-reduced sample was measured using
the Bradford protein assay reagent from Bio-Rad. Serine/threonine
phosphatase activity was measured using a commercially available
assay following the manufacturer’s instructions (Promega).
RESULTS
IL-6 Induces MMP-13 Gene Transcription—To determine the
effects of IL-6 on MMP-13 gene expression, we examined the
steady-state levels of MMP-13 mRNA in Rat-1 fibroblasts
treated with increasing concentrations of IL-6 for 24 h. The
level of MMP-13 mRNA in each sample was normalized to the
level of 18 S RNA. This treatment resulted in a marked in-
crease in steady-state levels of MMP-13 mRNA (Fig. 1). Thus,
40 ng/ml IL-6 increased MMP-13 levels 3.4-fold over the control
level (Fig. 1A). Likewise, these levels were increased to 1.2-, 2-,
2.9-, and 3.2-fold more than the control level after 3, 6, 12, and
24 h, respectively, of incubation with 20 ng/ml IL-6 (Fig. 1B).
This increase was in the range of the increase induced with 0.6
nM tumor necrosis factor-a (2.4-fold) or 2 ng/ml IL-1 (3.8-fold) in
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these cells (Fig. 1C). The IL-6-induced increase in MMP-13
mRNA was abrogated by pretreating cells with 0.1 mM cyclo-
heximide (Fig. 1D), which decreases protein synthesis by 95%
in these cells (data not shown). As it has been described for
c-Fos and c-Jun (43), preincubation of cells with cycloheximide
resulted in an 3-fold increase in MMP-13 mRNA levels. How-
ever, this level was not further increased by incubating cells
with 20 or 40 ng/ml IL-6. These effects on MMP-13 mRNA were
associated with a dose-dependent increase in the amount of
immunoreactive MMP-13. This protein increased 5.9-, 8-, and
12-fold, respectively, after incubating the cells with 10, 20, or
40 ng/ml IL-6 for 24 h (Fig. 2A). The same experimental con-
ditions enhanced immunoreactive TIMP-1 only slightly. Treat-
ment of cells with 40 ng/ml IL-6 for 24 h increased TIMP-1 only
1.7-fold (Fig. 2B).
To identify the mechanism by which IL-6 increases collagen-
ase mRNA, a CAT reporter gene driven by a portion of the
MMP-13 gene promoter (p(21000)MMP-13-CAT) was trans-
fected into cultured Rat-1 fibroblasts and the levels of CAT
activity determined. This activity was normalized to the b-ga-
lactosidase activity of the cotransfected pRSV-b-galactosidase
plasmid. Four separate experiments showed that IL-6 in-
creased CAT activity and that this increase was dose- and
time-related (Fig. 3).
To determine the sequences on which IL-6 exerts its effects
on MMP-13 transcription, we transiently transfected cells with
a series of constructs obtained by progressively deleting more
59-flanking sequences of the MMP-13 gene promoter and in-
serting them into a CAT reporter plasmid. Deletion of promoter
sequences upstream of base pair 276 relative to the transcrip-
tion start site did not abrogate the effect of IL-6 on MMP-13
gene expression (Fig. 4, A–E). On the contrary, this effect of
IL-6 disappeared in cells transfected with a mutant construct
in which the proximal AP1 binding site have been converted
from GTGACTCA into GTTCCAAG (Fig. 4F).
To assess the role of the TRE sequence in the stimulation of
the MMP-13 gene, we transfected Rat-1 fibroblasts with a
plasmid containing two copies of the TRE upstream of the
herpes simplex virus-tk promoter (p2xTRE-Luc) and measured
the effect of increasing concentrations of IL-6 on the luciferase
activity in cell lysates. We found that 20 ng/ml IL-6 increased
luciferase activity 1.4-fold the control level at 6 h and reached
1.9- and 2.6-fold at 12 and 24 h, respectively (Fig. 5). The
increased luciferase activity was more marked in cells incu-
bated with 40 ng/ml IL-6, where there was a 1.9-, 2.7-, and
3.1-fold induction at 6, 12, and 24 h, respectively (Fig. 5).
IL-6 Increases AP1 Binding to DNA—To determine whether
IL-6 induces the DNA binding activity of AP1, we examined the
kinetics of AP1 binding activity in IL-6 stimulated cells. Nu-
clear extracts were prepared from Rat-1 fibroblasts treated
with 20 ng/ml IL-6 for 1–6 h. A 32P-labeled oligonucleotide
containing the AP1 consensus sequence was used as a probe.
AP1 binding activity increased 1.9-fold (Fig. 6A) and 2.4-fold
(Fig. 6B) over the control level after 6 and 24 h, respectively.
Likewise, AP1 binding to DNA was only slightly enhanced
(1.2-fold) in cells treated with 5 ng/ml IL-6 for 24 h, but rose to
1.8-, 2.4-, and 2.6-fold with 10, 20, and 30 ng/ml IL-6, respec-
tively, for the same period of time (Fig. 6B). This binding was
efficiently competed with 200-fold molar excess of the same
unlabeled oligonucleotide (Fig. 6), but not with 200-fold molar
excess of an unlabeled oligonucleotide containing a C/EBP con-
sensus binding site (Fig. 6A). On the other hand, incubation of
the nuclear extract with a phosphorylated c-Jun-specific anti-
body prior to the gel retardation assay led to the formation of
two supershifted complexes (Fig. 6A), demonstrating that phos-
phorylated c-Jun was a member of this complex.
IL-6 Enhances c-fos and c-jun Gene Expression—Because
AP1 is a collection of transcriptional factors composed of mem-
FIG. 1. Northern blot analysis of Rat-1 fibroblasts MMP-13
mRNA. A, dose-response effect of IL-6 on MMP-13 mRNA. Confluent
Rat-1 fibroblasts were incubated for 24 h in Dulbecco’s modified Eagle’s
medium without fetal calf serum in the absence or presence of increas-
ing concentrations of IL-6. B, time-response effect of 20 ng/ml IL-6 on
MMP-13 mRNA. C, effect of 0.6 nmol/liter tumor necrosis-a, 20 ng/ml
IL-6, and 2 ng/ml IL-1 for 24 h on MMP-13 mRNA. D, MMP-13 mRNA
in cells incubated for 24 h in control medium or in medium containing
20 or 40 ng/ml IL-6 in the presence or absence of 0.1 mM cycloheximide
(CHX). Five micrograms of total RNA were electrophoresed on a form-
aldehyde, 1% agarose gel and transferred to a nylon filter by capillary
blotting. Bound RNA was hybridized to 32P-labeled cDNA probe as
described under “Experimental Procedures.” The filters were exposed to
x-ray film at 270 °C with an enhancing screen. The autoradiograms
were quantitated by scanning laser densitometry. The level of MMP-13
mRNA in each sample was normalized to the level of 18 S RNA (18S).
These blots are representative of three separate experiments.
FIG. 2. Effect of treatment of cells with IL-6 on immunoreac-
tive MMP-13 and TIMP-1 proteins. A, samples of medium without
fetal calf serum (0.5 mg of protein) harvested from cells untreated and
treated with 10, 20, or 40 ng/ml IL-6 for 24 h were analyzed by Western
blot with polyclonal antibody against human MMP-13 as described
under “Experimental Procedures.” B, samples of medium harvested
from cells untreated or treated with 10–40 ng/ml IL-6 were concen-
trated, and 30 mg protein from each sample were analyzed by Western
blot with specific polyclonal antibody against rat TIMP-1. MW, molec-
ular mass.
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bers of the Jun and Fos families (44), we investigated whether
IL-6 treatment of cells was associated with an activation of the
jun or fos genes. Incubation of cells with 5–30 ng/ml IL-6 for
24 h resulted in enhanced induction of c-Jun, JunB, and c-Fos
mRNA. Thus, in cells treated with 20 ng/ml IL-6, mRNA levels
of these three proteins were increased 5.5-, 4.3-, and 3.9-fold
(Fig. 7). To assess the role of IL-6 on c-jun and c-fos transcrip-
tion, cells were transfected with the plasmids pJun-Luc or
pFos-Luc. Cells transfected with pJun-Luc and treated with 20
or 30 ng/ml of IL-6 for 7 h resulted in an increase in luciferase
activity by 2.6- and 3.6-fold, respectively. At 12 h, this activity
was slightly lower than at 7 h, and at 24 h, these levels were
decreased only to 1.6- and 1.7-fold (Fig. 8A). Treatment of cells
transfected with pfos-Luc with 20 and 30 ng/ml of IL-6 for 7 h
increased luciferase activity only by 43 and 61%, respectively,
over the control level, and 24 and 17%, respectively, after 24 h
(Fig. 8B).
To assess whether IL-6 induces AP1 proteins, whole cell
protein extracts were prepared from Rat-1 fibroblasts treated
with increasing concentrations of IL-6 for 12 h. IL-6 induced a
dose-dependent increase in a 39-kDa protein, the nonphospho-
rylated c-Jun, (41, 42) (Fig. 9, A and B). Likewise, Western
blots using specific polyclonal c-Fos antibody showed an in-
crease in the expression of c-Fos p62 protein (Fig. 9, C and D).
Because phosphorylation of c-Jun plays a critical role in the
activation of gene transcription, we analyzed phosphorylated
c-Jun with a specific monoclonal antiphosphorylated c-Jun an-
tibody, directed at the phosphorylated activation domain. As a
positive control for this protein, we included whole cell proteins
extracted from Junkat cells treated with 25 ng/ml of PMA.
Western blot analysis revealed one single band located at 41
kDa, the density of which increased after incubation with IL-6
(20 ng/ml), reached its maximal density after 12 h (8.5-fold)
(Fig. 10A), and then declined slowly over the next 12 h (Fig.
10B). Treatment of cells with higher doses of IL-6 (80 ng/ml)
enhanced phosphorylated c-Jun only 1.9-fold (Fig. 10C).
Because IL-6 increased phosphorylation of the c-Jun activa-
tion domain, we measured JNK activity in Rat-1 fibroblasts
treated with IL-6 for 15 min. JNK activity was measured using
a previously described solid-state assay using GST-c-Jun as
substrate (41). Incubation of cells with 10 and 20 ng/ml IL-6
decreased JNK activity to 80 and 60%, respectively, of that of
control cells (Fig. 10D).
IL-6 Inhibits Serine/Threonine Phosphatase—Because IL-6
enhanced phosphorylation of the c-Jun activation domain with-
out enhancing JNK activity, we wanted to determine whether
IL-6 inactivates a serine/threonine phosphatase. Measurement
of the serine/threonine phosphatase activity in Rat-1 fibro-
blasts treated with increasing concentration of IL-6 for 6 h
showed that IL-6 decreased phosphatase activity in a dose-de-
pendent fashion. Treatment of cells with 20 or 40 ng/ml IL-6
decreased this activity to 39 or 22%, respectively, of control
activity (Fig. 11A). Likewise, incubation of cells with 20 ng/ml
IL-6 for 3–24 h resulted in a decrease of serine/threonine phos-
FIG. 3. Effect of IL-6 on collagenase gene promoter in Rat-1
fibroblasts. Cells were transfected by the LipofectAMINE method
with 1.5 mg of p(21000)MMP-13-CAT reporter plasmid and 0.6 mg of
pRSV-b-galactosidase plasmid. One day after transfection, the cells
were incubated with 0, 10, 20, or 40 ng/ml of IL-6 in the absence of fetal
calf serum for 6, 12, 24, or 48 h. After the indicated time, cells were
harvested, and CAT and b-galactosidase activities were measured in
the homogenates as described under “Experimental Procedures.” CAT
activity was normalized to b-galactosidase activity as an internal stand-
ard for transfection efficiency. Values are given as cpm corrected by the
b-galactosidase activity. The results represent the mean 6 SD of
one experiment performed in triplicate. *, p , 0.05; **, p , 0.01; ***,
p , 0.001, as compared with control cells.
FIG. 4. Deletion analysis of the MMP-13 gene promoter. Rat 1
fibroblasts were transiently cotansfected with pRSV-b-galactosidase
plasmid, and a series of MMP-13-CAT constructs was obtained by
removing progressively more 59-flanking sequences of the MMP-13
promoter. p(22000)MMP-13-CAT contained nucleotides 22000 to 127
of the MMP-13 promoter inserted into the vector plasmid pSVO-CAT.
Fragments of MMP-13 promoter contained in plasmids p(21000)MMP-13-
CAT, p(2500)MMP-13-CAT, p(2284)MMP-13-CAT, and p(276)MMP-13-
CAT were 21000, 2500, 2284 and 276 to 127, respectively. The mutated
plasmid p(276)MMP-13-CATm was similar to p(276)MMP-13-CAT, but
the proximal TRE has been scrambled. Cell lysates were assayed for CAT
and b-galactosidase activities as described in Fig. 2 and under “Experimen-
tal Procedures.” Because CAT activity in cell lysate decreased with the
length of the portion of MMP-13 promoter contained in each of these con-
structs, we used increasing amounts of cell lysate to measured CAT activity.
Thus, we used 2.5, 2.5, 5, 20, 45, and 45 ml of cell lysate from cells transfected
with p(22000)MMP-13-CAT (A), p(21000)MMP-13-CAT (B), p(2500)MMP-
13-CAT (C), p(2284)MMP-13-CAT (D), p(276)MMP-13-CAT (E), and
p(276)MMP-13-CATm (F), respectively. G, the effect of IL-6 on the empty
vector pSVO-CAT. The results presented are representative of three sepa-
rate experiments. AC, acetylated chloramphenicol; C, radiolabeled
chloramphenicol.
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phatase activity, which was particularly marked at 6 h (44%).
At 12 and 24 h, this activity was higher than at 6 h (50 and
53%, respectively, of control) (Fig. 11B).
DISCUSSION
We show that IL-6 increased the steady-state levels of
MMP-13 mRNA in a dose- and time-dependent manner (Fig. 1)
and that this effect mediated within the gene promoter (Fig. 3).
This effect was evident after 6 h of treatment but was partic-
ularly marked after 24 h. This prolonged incubation time re-
quired by IL-6 to stimulate MMP-13 gene expression and
MMP-13 mRNA levels suggests that de novo synthesis of a
protein may be required for this effect. This requirement is
supported by the fact that the IL-6-induced increase in
MMP-13 mRNA levels was blocked by inhibiting protein syn-
thesis with cycloheximide (Fig. 1D). As expected, the enhanced
MMP-13 gene expression was associated with a striking in-
crease in the immunoreactive MMP-13 protein (Fig. 2A). These
results agree with those reported by Franchimont et al. (25)
and Kusano et al. (45), who demonstrated that IL-6, in the
presence of its soluble receptor, increased MMP-13 mRNA lev-
els (25, 45), immunoreactive MMP-13 (25), and its biological
activity (25). Our study demonstrated that the effect of IL-6 on
MMP-13 secreted into the culture medium was much higher
than that induced on the steady-state levels of MMP-13 mRNA.
We speculate that this difference might be ascribed to an effect
of IL-6 on the extracellular metabolism of secreted MMP-13. In
fact, Sehgal and Thompson (46) recently showed that trans-
forming growth factor b1 induced a marked increase in stabil-
ity of MMP-2 protein, resulting in a significantly enhanced
MMP-2 protein level in culture medium, despite an unchanged
steady-state level of MMP-2 mRNA. Although some authors
have shown that IL-6 significantly enhanced TIMP-1 produc-
tion and TIMP-1 mRNA expression in human fibroblasts and
other cell lines (17, 22, 25–28), we found that IL-6 increased
immunoreactive TIMP-1 only slightly (Fig. 2B).
Rat MMP-13 gene displays a general organization similar to
that of other members of the MMP family (47, 48), particularly
to human (49) and rabbit MMP-1 genes (50). All share a com-
mon 10-exon organization (48, 49, 51) and contain a typical
TATA box in addition to TRE and polyomavirus enhancer ac-
tivator 3 (PEA-3) consensus sites in their promoter region (15,
48, 52–57), suggesting a common regulatory mechanism of
gene transcription. Our study showed that sequences upstream
FIG. 5. Effect of IL-6 on TRE in Rat-1 fibroblasts. Cells were
transfected as indicated under “Experimental Procedures” with 0.5 mg
of p2xTRE-Luc, 0.5 mg of pRSV-b-galactosidase, and 1.1 mg of pUC19
and cultured without fetal calf serum in the absence or presence of 20
or 40 ng/ml IL-6 for 6, 12, or 24. After the indicated time, luciferase and
b-galactosidase activities were measured as mentioned. Values are
given as fold over the activity in cells incubated without IL-6. Results
represent mean values 6 SD. *, p , 0.05; **, p , 0.01; ***, p , 0.001,
as compared with control cells.
FIG. 6. Mobility shift assays using the AP1 probe. DNA binding
was analyzed by gel retardation assay as described under “Experimen-
tal Procedures.” A, time course of AP1 activation in response to IL-6 for
1–6 h. A double-stranded radiolabeled AP1 oligonucleotide was incu-
bated with nuclear proteins extracted from control cells or cells treated
with 20 ng/ml IL-6. B, nuclear extracts from cells treated for 24 h with
increasing concentrations of IL-6 were incubated with radiolabeled AP1
probe. Lanes P, AP1 radiolabeled probe without addition of nuclear
extract. Lanes C, probe incubated with nuclear proteins extracted from
control cells. Lanes 6a and 20a, nuclear protein extract from cells
treated for 6 and 24 h, respectively, with 20 ng/ml IL-6 incubated with
radiolabeled AP1 probe in the presence of 200-fold molar excess of
unlabeled AP1 oligonucleotide. Lane 6b, supershift after incubation of
the reaction mix with specific phosphorylated c-Jun antibody prior to
the gel retardation assay. Lane Ca, nuclear protein extract from control
cells incubated with radiolabeled AP1 probe. Lane Cb, nuclear protein
extract from control cells in the presence of 200-fold molar excess of
unlabeled C/EBP oligonucleotide. Lane Cc, supershift after incubation
of the reaction mix with specific C/EBP antibody (aebp). The results
presented are representative of four separate experiments. NE, nuclear
protein extract; comp., competitor; Ab., antibody; apJ, anti-phosphory-
lated c-Jun antibody; AP, unlabeled AP1 oligonucleotide, ebp, C/EBP
oligonucleotide; probe, radiolabeled probe.
FIG. 7. c-Jun, JunB, and c-Fos mRNA are induced by IL-6. Total
RNA was isolated from Rat-1 fibroblasts cultured with 0–30 ng/ml IL-6
for 24 h and analyzed by Northern blotting as described under “Exper-
imental Procedures.” The blot was hybridized with 32P-labeled probes
specific for c-Jun, JunB, c-Fos, and 18 S RNA, which served as a control
for sample loading. Autoradiograms were quantitated by scanning laser
densitometry. The level of mRNA in each sample was normalized to the
level of 18 S RNA. Blots are representative of at least three separate
experiments.
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of base pair 279 are dispensable in IL-6-mediated stimulation
of MMP-13 gene expression, whereas integrity of the TRE site
appears to be essential for the IL-6 induced response (Fig. 4).
The TRE has been implicated in the expression of many of the
MMP genes (58, 59), including MMP-13 (59). However, some of
these genes (60, 61) require the cooperative action of the TRE
with the PEA-3 element to obtain maximal inductability by a
number of stimuli. The present study shows that PEA-3 was
not required to obtain a response to IL-6 (Fig. 4). These results
concur with those reported by Pendás et al. (48), who showed
that PEA-3 was not significant in the response of the human
MMP-13 to 12-O-tetradecanoylphorbol-13-acetate. These dis-
crepancies between the role played by the PEA-3 site in human
and rat MMP-13 and its role in other members of the MMP
family may be ascribed to the distance existing between TRE
and PEA-3 elements (48). Whereas human and rat MMP-13
contain 20 nucleotides between TRE and PEA-3 sites, the dis-
tance between these two elements is only 9 nucleotides in other
MMP genes.
The stimulatory effect of IL-6 on the TRE site was also
confirmed in cells transfected with a luciferase construct con-
taining two copies of the TRE upstream of a minimal promoter
(Fig. 5). Very little information exists about the effect of IL-6 on
the activation of genes with a TRE. Daffada et al. (62) found
that IL-6 had no effect on the expression of pTRE-CAT in
transient transfected cells, suggesting that AP1 is not induced
by IL-6 treatment. On the contrary, Melamed et al. (63) showed
that IL-6 induced a TRE-binding complex, which was abolished
by anti-Jun specific antibodies.
To confirm that IL-6 promotes the binding of nuclear pro-
teins to the TRE, gel retardation experiments were performed
(Fig. 6). Treatment of cells with IL-6 induced a dose- and
time-related increase in the formation of a TRE-protein com-
plex (Fig. 6) that contained phosphorylated c-Jun. These re-
sults support the role played by TRE and AP1 in mediating the
effect of IL-6 on rat MMP-13 gene expression.
The AP1 transcription factor actually represents a heteroge-
neous group composed of members of the Jun and Fos families.
These proteins form a variety of homo- and heterodimers that
bind to a common DNA recognition site (25, 64). In this study
we showed that IL-6 induced c-Jun, JunB and c-Fos mRNA
(Fig. 7), c-jun and c-fos promoters (Fig. 8A) and c-Jun and c-Fos
proteins in Rat-1 fibroblasts (Fig. 9). Other authors have also
shown that IL-6 stimulated junB gene expression in a variety
of cells (65–74) by acting on a region containing an ETS and a
STAT3 binding site (67, 69, 72). More recently, Cressman et al.
(75) have shown that the expression of junB and STAT3 are
markedly reduced in the liver of IL-6-deficient mice.
The increase in c-Fos mRNA seems to be only partially due to
enhanced transcriptional activity, because luciferase activity in
cells transiently transfected with the plasmid pFos-Luc in-
creased only slightly after IL-6 treatment. There are few stud-
ies concerning the effect of IL-6 on c-fos gene expression or Fos
protein. However, a number of authors have found the induc-
tion of c-fos gene in a variety of cells (71, 76, 77) and Cressman
et al. (75) reported that hepatectomy induced the expression of
c-Fos protein in the liver of control mice but was reduced or
absent in the livers of IL-6-knockout mice. Nevertheless, other
FIG. 8. Effect of IL-6 on c-jun and c-fos promoter activity. Rat-1
fibroblasts were transfected as indicated in Fig. 2 with 0.5 mg pJun-Luc
(A) or pFos-Luc (B) as reporter plasmids plus 0.5 mg of pRSV-b-galac-
tosidase and 1.1 mg of pUC19 plasmids. Transfected cells were incu-
bated with 0–30 ng/ml IL-6 for 3–24 h. After the indicated time, cells
were harvested and luciferase, and b-galactosidase activities were
measured in homogenates. Luciferase values were normalized for dif-
ferences in transfection efficiencies. Fold represents luciferase/b-galac-
tosidase ratio in the presence of IL-6 divided by that obtained in the
absence of IL-6. Data are the means 6 SD of one experiment with
triplicate determinations. *, p , 0.05; **, p , 0.01; ***, p , 0.001, as
compared with the control cells.
FIG. 9. Kinetic of induction of c-Jun and c-Fos proteins by IL-6.
Twenty-five micrograms of whole cell protein extracts from cells incu-
bated in the absence or presence of increasing concentrations of IL-6 for
1–8 h were separated by 8% SDS-polyacrylamide gel electrophoresis
and transferred to membrane for immunoblot analysis as described
under “Experimental Procedures.” Ponceau S staining was used to
confirm equal protein loading. Immunoblots were then probed with
either specific anti-c-Jun (A and B) or anti-c-Fos (C and D) antibodies
and detected by enhanced chemiluminescence. Whole cell protein ex-
tract from J-Jhan cells treated with 25 ng/ml PMA was used as positive
control of c-Jun and c-Fos (Junkat PMA). Blots are representative of at
least three separate experiments.
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authors, working on a variety of cells lines, could not demon-
strate any effect of IL-6 on c-fos. These studies showed that
only some early response genes, such as the jun family, but not
c-myc or c-fos, were stimulated by the addition of IL-6 (66–68).
Transcriptional activity of AP1 depends not only on the
abundance of AP1 components and their ability to bind DNA
but also on the degree of phosphorylation of these proteins (64).
Phosphorylation of c-Jun in its activation domain at serine 63
and 73 prolongs its half-life and potentiates the ability of c-Jun
to activate transcription as either a homodimer or as a het-
erodimer with c-Fos (64). Western blots using a specific mono-
clonal antibody for serine 63 phosphorylated c-Jun demon-
strated that IL-6 induces an increase in this form of c-Jun,
which was particularly marked after 12 h of treatment (Fig.
10). This result concurred with the study of Lütticken et al.
(70), who showed that IL-6 triggers a delayed phosphorylation
of STAT3 at serine residues. A variety of protein kinases,
including pp42, pp54, and pp44 mitogen-activated protein ki-
nases, p34cdc2, protein kinase C, casein kinase II, efficiently
phosphorylates c-Jun (78). JNK, also known as stress-activated
protein kinase, is a member of the mitogen-activated protein
kinase family that phosphorylates serines 63 and 73 of c-Jun
and potentiates its transactivation function (42). However, our
study indicates that IL-6 does not induce the phosphorylation
of c-Jun by stimulating JNK activity (Fig. 10D). Therefore, we
have to consider that the increase in phosphorylated c-Jun is
the result of either a decrease in protein phosphatase activity
or an activation of another protein kinase involved in the phos-
phorylation of c-Jun (78). Thus, a number of studies have
clearly demonstrated that inhibition of protein phosphatases 1
and 2A by okadaic acid results in an induction of collagenase,
JunB, and c-Fos mRNA and a potent activation of AP1, through
serine/threonine phosphorylation (79–81). The results of our
study concur with these reports by demonstrating that treat-
ment of cells with IL-6 decreased serine/threonine phosphatase
activity in a dose-dependent manner and that this effect was
particularly marked at 6 h of treatment (Fig. 11). Despite that,
we cannot exclude the participation of another protein kinase.
In fact, Belka et al. (82) found that IL-6-mediated phosphoryl-
ation of the small heat shock protein 27 was the result from
activation of the mitogen-activated protein-kinase-activated
protein kinase 2, a serine/threonine kinase that is activated by
mitogen-activated protein kinase.
In conclusion, this study shows that treatment of Rat 1
fibroblasts with IL-6 stimulated MMP-13 gene expression in a
time- and dose-dependent manner. This effect was associated
with an enhanced expression of jun and fos genes, an increase
in the DNA-binding activity of AP1, and an elevation of phos-
phorylated c-Jun. The latter increase was not mediated by
enhanced JNK activity but was associated with decreased ser-
ine/threonine phosphatase activity.
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70. Lütticken, C., Coffer, P., Yuan, J., Schwartz, C., Caldenhover, E., Schindler,
C., Kruijer, W., Heinrich, P. C., and Horn, F. (1995) FEBS Lett. 360,
137–143
71. Jenab, S., and Morris, P. L. (1997) Endocrinology 138, 2740–2746
72. Kojima, H., Nakajima, K., and Hirano, T. (1996) Oncogene 12, 547–554
73. Nakajima, K., and Wall, R. (1991) Mol. Cell. Biol. 11, 1409–1418
74. Lord, K. A., Abdollahi, A., Thomas, S. M., DeMarco, M., Brugge, J. S.,
Hoffman-Liebermann, B., and Liebermann, D. A. (1991) Mol. Cell. Biol. 11,
4371–4379
75. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth,
E. E., Poli, V., and Taub, R. (1996) Science 274, 1379–1383
76. Satoh, T., Nakamura, S., Taga, T., Mastuda, T., Hirano, T., Kishimoto, T., and
Kaziro, Y. (1988) Mol. Cell. Biol. 8, 3546–3549
77. Henschler, R., Lindemann, A., Brach, M. A., Mackensen, A., Mertelsmann,
R. H., and Herrmann, F. (1991) FEBS Lett. 283, 47–51
78. Baker, S. J., Kerppola, T. K., Luk, D., Vandenberg, M. T., Marshak, J. R.,
Curran, T., and Abate, C. (1992) Mol. Cell. Biol. 12, 4694–4705
79. Westermarck, J., Lohi, J., Keski-Oja, J., and Kaharri, V. M. (1994) Cell Growth
Differ. 5, 1205–1213
80. Kim, S. J., Lafyatis, R., Kim, K. Y., Angel, P., Fujiki, H., Karim, M., Sporn,
M. B., and Roberts, A. B. (1990) Cell Regul. 1, 269–278
81. Thevenin, C., Kim, S. J., and Kehrl, J. H. (1991) J. Biol. Chem. 266, 9363–9366
82. Belka, C., Ahlers, A., Sott, C., Gaestel, M., Herrmann, F., and Brach, M. A.
(1995) Leukemia 9, 288–294
IL-6 Activates Metalloproteinase-13 Gene Expression30926
